Alluvi, formerly BI 4744, presents a significant development in obesity treatment. This dual activator targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide targets demonstrates https://alluvi860576.boonblog.com/61821548/alluvi-a-detailed-dive-into-the-drug-s-prospects